Emerging retatrutide, a twin -action drug targeting simultaneously GLP-1 and GIP receptors, is creating considerable interest within the healthcare community. Initial clinical studies have revealed substantial losses in overall weight and gains in physiological markers for people with excess weight . Researchers believe this unique approach may rep